CL2012003350A1 - Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares. - Google Patents

Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares.

Info

Publication number: CL2012003350A1
Authority: CL; Chile
Prior art keywords: drug; risperidone; lactic; copolymer; viscosity
Prior art date: 2010-05-31

Application number

CL2012003350A

Other languages

English (en)

Inventor

Aduriz Ibon Gutiero

Ochoa Maria Teresa Gomez

Original Assignee

Rovi Lab Farmaceut Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-31

Filing date

2012-11-29

Publication date

2013-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43301889&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003350(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-29 Application filed by Rovi Lab Farmaceut Sa filed Critical Rovi Lab Farmaceut Sa

2013-10-18 Publication of CL2012003350A1 publication Critical patent/CL2012003350A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)

CL2012003350A 2010-05-31 2012-11-29 Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares. CL2012003350A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10382154.2A EP2394664B1 (en)	2010-05-31	2010-05-31	Antipsychotic injectable depot composition

Publications (1)

Publication Number	Publication Date
CL2012003350A1 true CL2012003350A1 (es)	2013-10-18

Family

ID=43301889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003350A CL2012003350A1 (es)	2010-05-31	2012-11-29	Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares.

Country Status (32)

Country	Link
US (2)	US10085936B2 (es)
EP (2)	EP2394664B1 (es)
JP (1)	JP5882993B2 (es)
KR (1)	KR101784330B1 (es)
CN (1)	CN103002917B (es)
AP (1)	AP3524A (es)
AU (1)	AU2011260318B2 (es)
BR (1)	BR112012030686B1 (es)
CA (1)	CA2800111C (es)
CL (1)	CL2012003350A1 (es)
CY (2)	CY1117964T1 (es)
DK (2)	DK2394664T3 (es)
EA (1)	EA024155B1 (es)
ES (2)	ES2589106T3 (es)
HR (2)	HRP20161049T1 (es)
HU (2)	HUE029895T2 (es)
IL (1)	IL223129A (es)
LT (2)	LT2394664T (es)
MA (1)	MA34296B1 (es)
ME (1)	ME02501B (es)
MX (1)	MX338373B (es)
MY (1)	MY161930A (es)
NZ (1)	NZ604342A (es)
PL (2)	PL2394664T3 (es)
PT (2)	PT2394664T (es)
RS (1)	RS55190B1 (es)
SG (1)	SG185775A1 (es)
SI (2)	SI2394664T1 (es)
SM (2)	SMT201600321B (es)
UA (1)	UA108885C2 (es)
WO (1)	WO2011151355A1 (es)
ZA (1)	ZA201209346B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8852638B2 (en)	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
BRPI0811319A2 (pt)	2007-05-25	2015-02-10	Tolmar Therapeutics Inc	Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US10285936B2 (en)	2010-05-31	2019-05-14	Laboratorios Farmacéuticos Rovi, S.A.	Injectable composition with aromatase inhibitor
US10350159B2 (en)	2010-05-31	2019-07-16	Laboratories Farmacéuticos Rovi, S.A.	Paliperidone implant formulation
US10335366B2 (en) *	2010-05-31	2019-07-02	Laboratorios Farmacéuticos Rovi, S.A.	Risperidone or paliperidone implant formulation
PT2394663T (pt)	2010-05-31	2021-11-26	Farm Rovi Lab Sa	Composições para implantes biodegradáveis injectáveis
US10881605B2 (en)	2010-05-31	2021-01-05	Laboratorios Farmaceuticos Rovi, S.A.	Methods for the preparation of injectable depot compositions
US10463607B2 (en)	2010-05-31	2019-11-05	Laboratorios Farmaceutics Rofi S.A.	Antipsychotic Injectable Depot Composition
DK2394664T3 (en)	2010-05-31	2016-09-12	Laboratorios Farmacéuticos Rovi S A	Antipsychotic injectable depot composition
SI2529757T1 (sl) *	2011-05-31	2014-05-30	Laboratorios Farmaceuticos Rovi, S.A.	Formulacija paliperidon implantata
DK2529756T3 (da) *	2011-05-31	2021-08-02	Farm Rovi Lab Sa	Risperidon- og/eller paliperidon-implantatformulering
BR112015022023B1 (pt)	2013-03-11	2022-12-06	Durect Corporation	Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
US20140308352A1 (en)	2013-03-11	2014-10-16	Zogenix Inc.	Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2016199170A2 (en) *	2015-06-10	2016-12-15	Cipla Limited	Paliperidone palmitate particles and compositions thereof
JP2020511483A (ja)	2017-03-20	2020-04-16	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｔｅｒｎａｔｉｏｎａｌＧｍｂＨ	徐放性オランザピン製剤
CN109589304A (zh) *	2017-10-01	2019-04-09	万特制药(海南)有限公司	利培酮口服溶液及其制备方法
CN110420212A (zh) *	2019-08-19	2019-11-08	韩自勤	一种用于治疗精神***症组合物及其制备方法
TW202313047A (zh)	2021-09-21	2023-04-01	西班牙商禾霏藥品實驗室有限公司	抗精神病可注射儲積型組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
BE758156R (fr)	1970-05-13	1971-04-28	Ethicon Inc	Element de suture absorbable et sa
US4389330A (en)	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
US4530840A (en)	1982-07-29	1985-07-23	The Stolle Research And Development Corporation	Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en)	1982-10-22	1985-06-18	Kaplan Donald S	Polymers for injection molding of absorbable surgical devices
US4938763B1 (en)	1988-10-03	1995-07-04	Atrix Lab Inc	Biodegradable in-situ forming implants and method of producing the same
US5620700A (en)	1990-10-30	1997-04-15	Alza Corporation	Injectable drug delivery system and method
US5656297A (en) *	1992-03-12	1997-08-12	Alkermes Controlled Therapeutics, Incorporated	Modulated release from biocompatible polymers
KR100354270B1 (ko)	1993-11-19	2003-02-11	알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii	마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
ATE318580T1 (de)	1996-12-20	2006-03-15	Alza Corp	Gelzusammensetzungen und verfahren
US6143314A (en)	1998-10-28	2000-11-07	Atrix Laboratories, Inc.	Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en)	1998-10-28	2003-05-20	Atrix Laboratories	Polymeric delivery formulations of leuprolide with improved efficacy
US6331317B1 (en) *	1999-11-12	2001-12-18	Alkermes Controlled Therapeutics Ii Inc.	Apparatus and method for preparing microparticles
DE10190041D2 (de) *	2000-01-11	2002-12-05	Roland Bodmeier	Implantate, Partikel
US6604561B2 (en) *	2000-02-11	2003-08-12	Medical Instill Technologies, Inc.	Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
MXPA05001244A (es) *	2002-07-31	2005-06-08	Alza Corp	Composiciones de deposito de polimero multimodal inyectable y usos de las mismas.
WO2004064752A2 (en) *	2003-01-22	2004-08-05	Alkermes Controlled Therapeutics, Inc.	Method of preparing sustained release microparticles
US20050003007A1 (en)	2003-07-02	2005-01-06	Michele Boix	Method of sterilization of polymeric microparticles
US8343513B2 (en) *	2003-07-18	2013-01-01	Oakwood Laboratories, Llc	Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8221778B2 (en)	2005-01-12	2012-07-17	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
DE102005031868A1 (de) *	2005-07-04	2007-01-18	Biotronik Vi Patent Ag	Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) *	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
US8076448B2 (en)	2006-10-11	2011-12-13	Tolmar Therapeutics, Inc.	Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
FR2908775B1 (fr) *	2006-11-17	2012-08-31	Biomatlante	Hydrogel et ses applications biomedicales
PT2115029E (pt)	2007-02-15	2015-10-26	Tolmar Therapeutics Inc	Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros
HUE030789T2 (en) *	2007-05-18	2017-06-28	Durect Corp	Improved depot formulation
BRPI0811319A2 (pt) *	2007-05-25	2015-02-10	Tolmar Therapeutics Inc	Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
CL2008003305A1 (es) *	2007-11-06	2009-06-05	M/S Panacea Biotec Ltd	Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
CN102119022B (zh) *	2008-08-12	2015-09-09	诺华股份有限公司	药物组合物
US10350159B2 (en)	2010-05-31	2019-07-16	Laboratories Farmacéuticos Rovi, S.A.	Paliperidone implant formulation
US10285936B2 (en)	2010-05-31	2019-05-14	Laboratorios Farmacéuticos Rovi, S.A.	Injectable composition with aromatase inhibitor
US10335366B2 (en)	2010-05-31	2019-07-02	Laboratorios Farmacéuticos Rovi, S.A.	Risperidone or paliperidone implant formulation
DK2394664T3 (en)	2010-05-31	2016-09-12	Laboratorios Farmacéuticos Rovi S A	Antipsychotic injectable depot composition
PT2394663T (pt)	2010-05-31	2021-11-26	Farm Rovi Lab Sa	Composições para implantes biodegradáveis injectáveis
SI2529757T1 (sl)	2011-05-31	2014-05-30	Laboratorios Farmaceuticos Rovi, S.A.	Formulacija paliperidon implantata
DK2529756T3 (da)	2011-05-31	2021-08-02	Farm Rovi Lab Sa	Risperidon- og/eller paliperidon-implantatformulering

2010
- 2010-05-31 DK DK10382154.2T patent/DK2394664T3/en active
- 2010-05-31 HU HUE10382154A patent/HUE029895T2/en unknown
- 2010-05-31 SI SI201031270A patent/SI2394664T1/sl unknown
- 2010-05-31 PL PL10382154.2T patent/PL2394664T3/pl unknown
- 2010-05-31 ES ES10382154.2T patent/ES2589106T3/es active Active
- 2010-05-31 LT LTEP10382154.2T patent/LT2394664T/lt unknown
- 2010-05-31 EP EP10382154.2A patent/EP2394664B1/en active Active
- 2010-05-31 PT PT103821542T patent/PT2394664T/pt unknown
2011
- 2011-05-31 JP JP2013512879A patent/JP5882993B2/ja active Active
- 2011-05-31 UA UAA201214486A patent/UA108885C2/ru unknown
- 2011-05-31 PL PL11725383.1T patent/PL2575890T3/pl unknown
- 2011-05-31 MY MYPI2012701044A patent/MY161930A/en unknown
- 2011-05-31 PT PT117253831T patent/PT2575890T/pt unknown
- 2011-05-31 ME MEP-2016-178A patent/ME02501B/me unknown
- 2011-05-31 SI SI201130939A patent/SI2575890T1/sl unknown
- 2011-05-31 AP AP2012006626A patent/AP3524A/xx active
- 2011-05-31 LT LTEP11725383.1T patent/LT2575890T/lt unknown
- 2011-05-31 EP EP11725383.1A patent/EP2575890B1/en active Active
- 2011-05-31 HU HUE11725383A patent/HUE029056T2/en unknown
- 2011-05-31 CN CN201180026475.2A patent/CN103002917B/zh active Active
- 2011-05-31 AU AU2011260318A patent/AU2011260318B2/en active Active
- 2011-05-31 CA CA2800111A patent/CA2800111C/en active Active
- 2011-05-31 BR BR112012030686-3A patent/BR112012030686B1/pt active IP Right Grant
- 2011-05-31 ES ES11725383.1T patent/ES2592527T3/es active Active
- 2011-05-31 MA MA35428A patent/MA34296B1/fr unknown
- 2011-05-31 EA EA201201569A patent/EA024155B1/ru unknown
- 2011-05-31 KR KR1020127033021A patent/KR101784330B1/ko active IP Right Grant
- 2011-05-31 MX MX2012013937A patent/MX338373B/es active IP Right Grant
- 2011-05-31 RS RS20160730A patent/RS55190B1/sr unknown
- 2011-05-31 WO PCT/EP2011/059000 patent/WO2011151355A1/en active Application Filing
- 2011-05-31 NZ NZ604342A patent/NZ604342A/en unknown
- 2011-05-31 SG SG2012087136A patent/SG185775A1/en unknown
- 2011-05-31 DK DK11725383.1T patent/DK2575890T3/en active
2012
- 2012-11-19 IL IL223129A patent/IL223129A/en active IP Right Grant
- 2012-11-29 CL CL2012003350A patent/CL2012003350A1/es unknown
- 2012-11-30 US US13/690,647 patent/US10085936B2/en active Active
- 2012-12-10 ZA ZA2012/09346A patent/ZA201209346B/en unknown
2016
- 2016-08-19 HR HRP20161049TT patent/HRP20161049T1/hr unknown
- 2016-08-29 HR HRP20161100TT patent/HRP20161100T1/hr unknown
- 2016-08-31 CY CY20161100858T patent/CY1117964T1/el unknown
- 2016-08-31 CY CY20161100857T patent/CY1117969T1/el unknown
- 2016-09-15 SM SM201600321T patent/SMT201600321B/it unknown
- 2016-09-15 SM SM201600320T patent/SMT201600320B/it unknown
2018
- 2018-04-04 US US15/944,894 patent/US10182982B2/en active Active

Also Published As

Publication number	Publication date
KR101784330B1 (ko)	2017-10-11
DK2575890T3 (en)	2016-09-12
KR20130118742A (ko)	2013-10-30
MX338373B (es)	2016-04-13
BR112012030686B1 (pt)	2022-11-01
EP2575890B1 (en)	2016-06-01
SI2394664T1 (sl)	2016-10-28
US10182982B2 (en)	2019-01-22
CN103002917A (zh)	2013-03-27
US20180221272A1 (en)	2018-08-09
MY161930A (en)	2017-05-15
ZA201209346B (en)	2013-08-28
JP5882993B2 (ja)	2016-03-09
SG185775A1 (en)	2013-01-30
EP2394664B1 (en)	2016-06-01
US10085936B2 (en)	2018-10-02
PL2575890T3 (pl)	2016-12-30
EA201201569A1 (ru)	2013-04-30
CY1117969T1 (el)	2017-05-17
ES2589106T3 (es)	2016-11-10
AU2011260318B2 (en)	2014-11-27
BR112012030686A2 (pt)	2020-08-25
SMT201600321B (it)	2016-11-10
ES2592527T3 (es)	2016-11-30
EP2394664A1 (en)	2011-12-14
EA024155B1 (ru)	2016-08-31
JP2013528612A (ja)	2013-07-11
MA34296B1 (fr)	2013-06-01
NZ604342A (en)	2014-11-28
PT2394664T (pt)	2016-09-06
HRP20161049T1 (hr)	2016-12-30
ME02501B (me)	2017-02-20
CA2800111C (en)	2018-05-22
IL223129A (en)	2016-02-29
AP3524A (en)	2016-01-11
MX2012013937A (es)	2013-02-11
CY1117964T1 (el)	2017-05-17
PL2394664T3 (pl)	2016-12-30
UA108885C2 (uk)	2015-06-25
SI2575890T1 (sl)	2016-10-28
AU2011260318A1 (en)	2013-01-10
AP2012006626A0 (en)	2012-12-31
CN103002917B (zh)	2016-04-27
WO2011151355A1 (en)	2011-12-08
HUE029895T2 (en)	2017-04-28
EP2575890A1 (en)	2013-04-10
HRP20161100T1 (hr)	2016-11-04
DK2394664T3 (en)	2016-09-12
LT2394664T (lt)	2016-09-26
LT2575890T (lt)	2016-09-26
CA2800111A1 (en)	2011-12-08
PT2575890T (pt)	2016-09-06
RS55190B1 (sr)	2017-01-31
US20130171202A1 (en)	2013-07-04
HUE029056T2 (en)	2017-02-28
SMT201600320B (it)	2016-11-10
IL223129A0 (en)	2013-02-03

Publication	Publication Date	Title
CL2012003350A1 (es)	2013-10-18	Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares.
BRPI0908124A2 (pt)	2015-08-04	Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CO6771409A2 (es)	2013-10-15	Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
CL2012003722A1 (es)	2014-03-21	Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
BRPI0814666A2 (pt)	2017-05-09	composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CL2014003215A1 (es)	2015-07-10	Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion
CL2014003216A1 (es)	2015-07-10	Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion.
WO2012019426A8 (zh)	2012-05-10	酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2011019326A3 (en)	2011-04-28	Solubility and stability enchancing pharmaceutical formulation
WO2012019430A8 (zh)	2012-05-10	酞嗪酮类衍生物、其制备方法及其在医药上的应用
BRPI1006902A2 (pt)	2016-02-16	formulação farmacêutica ou alimentícia de liberação controlada, processo para a produção de uma forma farmacêutica ou alimentícia, sistema de liberação controlada, e, uso de um sistema de liberação controlada
EP3308785A3 (en)	2018-07-18	Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
WO2015120237A3 (en)	2015-11-05	4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
CO6640216A2 (es)	2013-03-22	Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112012003280A2 (pt)	2017-05-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BR112013014189A8 (pt)	2018-01-09	composição farmacêutica, uso de um agente de potencialização e uso de uma composição
BR112015021112A2 (pt)	2017-07-18	composições farmacêuticas que compreendem everolimo
WO2014101295A3 (zh)	2014-08-14	一种詹纳斯激酶（jaks）抑制活性的异恶唑衍生物
WO2011126839A3 (en)	2012-05-03	Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
BR112012015433B8 (pt)	2020-03-03	composição farmacêutica substancialmente anidra para aplicação cutânea
EP2549874A4 (en)	2013-10-02	SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
WO2014164648A3 (en)	2014-11-27	Solid state forms of a quinazoline derivative and its use as a braf inhibitor
EP3311809A4 (en)	2019-01-09	USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION